

January 23, 2026

To	To
<p><b>The Corporate Relations Department</b>  <b>BSE Limited</b>            Phiroze Jeejeebhoy Towers,            Dalal Street,            Mumbai – 400 001</p> <p><b>Code: 540222</b></p>	<p><b>The Listing Department</b>  <b>National Stock Exchange of India Ltd.,</b>            Exchange Plaza,            Bandra Kurla Complex, Bandra (E),            Mumbai – 400 051</p> <p><b>Code: LAURUSLABS</b></p>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

The Board of Directors of the Company at their meeting held on January 23, 2026 have resolved as follows:

**(1) Approval of Unaudited Financial Results for the quarter and nine-months ended December 31, 2025:**

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31, 2025 at their meeting held today i.e., January 23, 2026, which are enclosed herewith along with Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company.

The financial results are also available on the website of the Company at [www.lauruslabs.com](http://www.lauruslabs.com) and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively.

**(2) Noting of change in address of Corporate Office of the Company:**

The Board of Directors took note of the change in address of Corporate Office of the Company. The new Corporate office address is as follows:

**Plot No. 103, Road No. 1, Jubilee Hills, Hyderabad – 500033, Telangana, India.**

The Board Meeting commenced at 02.00 p.m and concluded at 02.40 p.m.

This is for your information and records.

Thanking you,

Yours sincerely,

**For Laurus Labs Limited**

**G. Venkateswar Reddy**  
 Company Secretary & Compliance Officer

Encl: A/a

**Registered Office**  
**Laurus Labs Limited**  
 Laurus Enclave, Plot Office 01, E. Bonangi Village,  
 Parawada Mandal, Anakapalli District – 531021, Andhra Pradesh, India.  
**T** +91 891 682 1101, 1102, **F** +91 891 682 1103  
**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**  
 Plot No. 103, Road No 1, Jubilee Hills,  
 Hyderabad, Telangana – 500 033, India.  
**T** +91 40 6659 4333  
**F** +91 40 6659 4320  
**CIN** : L24239AP2005PLC047518

LAURUS LABS LIMITED  
(CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021

Corp. Office: Plot No. 103, Road No. 1, Jubilee Hills, Hyderabad 500033, Telangana, India.

Tel: +91 040 6659 4333; Fax: +91 040 6659 4320; E-mail: [secretarial@lauruslabs.com](mailto:secretarial@lauruslabs.com); Website: [www.lauruslabs.com](http://www.lauruslabs.com)

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

₹ in Crores

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income</b>						
	(a) Revenue from operations	1,778.29	1,653.47	1,415.05	5,001.33	3,833.66	5,553.96
	(b) Other income	5.76	26.96	9.42	43.15	16.53	75.10
	<b>Total income</b>	<b>1,784.05</b>	<b>1,680.43</b>	<b>1,424.47</b>	<b>5,044.48</b>	<b>3,850.19</b>	<b>5,629.06</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	725.32	676.75	653.00	2,001.48	1,802.22	2,428.55
	(b) Purchase of traded goods	55.12	30.70	34.79	124.32	83.05	105.36
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(85.87)	(44.01)	(77.64)	(130.44)	(189.97)	(55.93)
	(d) Employee benefits expense (Refer note 9)	229.24	215.56	189.12	659.60	541.82	719.52
	(e) Other expenses	374.27	371.21	330.63	1,080.77	961.86	1,301.18
	(f) Depreciation and amortisation expense	120.62	120.49	106.09	357.95	319.66	430.09
	(g) Finance costs	38.79	40.00	57.80	130.29	159.60	216.00
	<b>Total expenses</b>	<b>1,457.49</b>	<b>1,410.70</b>	<b>1,293.79</b>	<b>4,223.97</b>	<b>3,678.24</b>	<b>5,144.77</b>
3	<b>Profit before tax (1-2)</b>	<b>326.56</b>	<b>269.73</b>	<b>130.68</b>	<b>820.51</b>	<b>171.95</b>	<b>484.29</b>
4	<b>Tax expense</b>						
	(a) Current tax	71.46	87.91	34.97	219.39	76.56	156.90
	(b) Deferred tax	1.99	(11.93)	5.10	(6.82)	(25.15)	(27.02)
	<b>Total Tax expense</b>	<b>73.45</b>	<b>75.98</b>	<b>40.07</b>	<b>212.57</b>	<b>51.41</b>	<b>129.88</b>
5	<b>Net Profit after tax (3-4)</b>	<b>253.11</b>	<b>193.75</b>	<b>90.61</b>	<b>607.94</b>	<b>120.54</b>	<b>354.41</b>
6	Share of profit/(loss) from associates and joint venture, net of tax	(1.23)	0.74	2.33	0.11	5.03	3.93
7	<b>Net Profit after taxes and share of profit from associates and joint venture (5+6)</b>	<b>251.88</b>	<b>194.49</b>	<b>92.94</b>	<b>608.05</b>	<b>125.57</b>	<b>358.34</b>
8	<b>Other comprehensive income</b>						
(a)	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) on defined benefit plans	(2.30)	(0.26)	0.38	(2.81)	1.14	(1.87)
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	0.58	0.07	(0.10)	0.71	(0.29)	0.50
	(iii) Share in Other comprehensive income of associates and joint venture, net of tax	-	(0.01)	-	(0.01)	-	(0.01)
(b)	Items that will be reclassified subsequently to profit or loss:						
	Exchange differences on translating the financial statements of foreign operations	0.12	(5.47)	(1.75)	(5.87)	(2.43)	(2.27)
	<b>Total other comprehensive loss, net of tax</b>	<b>(1.60)</b>	<b>(5.67)</b>	<b>(1.47)</b>	<b>(7.98)</b>	<b>(1.58)</b>	<b>(3.65)</b>
9	<b>Total comprehensive income (7+8)</b>	<b>250.28</b>	<b>188.82</b>	<b>91.47</b>	<b>600.07</b>	<b>123.99</b>	<b>354.69</b>
10	<b>Profit for the period attributable to:</b>						
	i) Equity holders of the company	251.66	194.97	92.30	609.65	124.65	358.32
	ii) Non-controlling interests	0.22	(0.48)	0.64	(1.60)	0.92	0.02
11	<b>Total comprehensive income for the period attributable to:</b>						
	i) Equity holders of the company	250.06	189.30	90.83	601.67	123.07	354.67
	ii) Non-controlling interests	0.22	(0.48)	0.64	(1.60)	0.92	0.02
12	Paid-up equity share capital (face value ₹ 2/- each)	107.97	107.96	107.85	107.97	107.85	107.85
13	Other equity						4,364.71
14	Earnings per equity share (face value ₹ 2/- each)						
	- Basic (₹)	4.67	3.61	1.71	11.30	2.31	6.65
	- Diluted (₹)	4.65	3.61	1.71	11.28	2.31	6.64
		(Net annualised)	(Net annualised)	(Net annualised)	(Net annualised)	(Net annualised)	(Annualised)

See accompanying notes to the financial results



**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E [info@lauruslabs.com](mailto:info@lauruslabs.com), W [lauruslabs.com](http://lauruslabs.com)

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Notes:


- The above consolidated unaudited financial results of Laurus Labs Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 23, 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025.
- These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The consolidated financial results include the results of the following entities:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Sriam Labs Private Limited	India	Subsidiary	100%
Laurus Holdings Limited	UK	Subsidiary	100%
Laurus Generics Inc	USA	Step-down subsidiary	100%
Laurus Generics GmbH	Germany	Step-down subsidiary	100%
Laurus Synthesis Private Limited	India	Subsidiary	100%
Laurus Generics SA (Pty) Ltd	South Africa	Subsidiary	100%
Laurus Bio Private Limited (Refer note 4b)	India	Subsidiary	78.34%
Laurus Specialty Chemicals Private Limited (Refer note 4a)	India	Subsidiary	100%
ImmunoAdoptive Cell Therapy Private Limited	India	Associate	34.89%
Ethan Energy India Private Limited	India	Associate	26.00%
KRKA Pharma Private Limited (Refer note 4c)	India	Joint Venture	49.00%

- a) The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations.
- b) During the quarter ended December 31, 2025, the company has invested ₹ 35 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F-Prime Capital ("Investors").
- c) Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited ("KRKA"), Capital contribution of ₹ 49 Crores have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31, 2025 for 49% stake. The Company has accounted for the investment in KRKA as joint venture.
- 5 Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited (Kurnool Renewables), capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30, 2025. The Company has accounted for its investment in Kurnool Renewables as an associate w.e.f May 12, 2025.
- 6 The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 7 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company for the quarter and nine months ended December 31, 2025, quarter ended September 30, 2025, quarter and nine months ended December 31, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger.
- 8 During the quarter ended December 31, 2025, the Company allotted 31,683 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- 9 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Group is in the process of evaluating the full impact of these new labour codes announced. The Group continues to monitor the finalisation of Central/State Rules and Clarifications from the Government on the other aspects of New Labour Code. The Group has estimated and accounted for incremental liability for employees of ₹ 8.3 Crores, which is not material to the financial results.

By order of the Board  
For Laurus Labs Limited

Dr. Satyanarayana Chava  
Whole Time Director & Chief Executive Officer



Place: Hyderabad  
Date : January 23, 2026



**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associates and joint venture for the quarter and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- a. Laurus Labs Limited, the Parent
- b. Laurus Bio Private Limited, India, Subsidiary
- c. Sriam Labs Private Limited, India, Wholly Owned Subsidiary
- d. Laurus Synthesis Private Limited, India, Wholly Owned Subsidiary
- e. Laurus Holdings Limited, United Kingdom, Wholly Owned Subsidiary
- f. Laurus Generics Inc., United States of America, (Subsidiary of (e) above)
- g. Laurus Generics GMBH, Germany, (Wholly Owned Subsidiary of (e) above)
- h. Laurus Generics SA (Pty) Ltd, South Africa, Wholly Owned Subsidiary
- i. Laurus Specialty Chemicals Private Limited, India, Wholly Owned Subsidiary
- j. ImmunoAdoptive Cell Therapy Private Limited, India, Associate
- k. Ethan Energy India Private Limited, India, Associate
- l. KRKA Pharma Private Limited, India, Joint venture

JK

**Deloitte  
Haskins & Sells LLP**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of ₹ 221.47 crores and ₹ 371.72 crores for the quarter and nine months ended December 31, 2025 respectively, total net profit after tax of ₹ 65.26 crores and ₹ 25.28 crores for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of ₹ 65.26 crores and ₹ 25.28 crores for the quarter and nine months ended December 31, 2025 respectively as considered in the Statement. This interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the Group's share of profit/(loss) after tax of ₹ (0.64) crores and ₹ 0.58 crores for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income/(loss) of ₹ (0.64) crores and ₹ 0.58 crores for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of an associate and one joint venture, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, this interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**C Manish Muralidhar**  
Partner  
Membership No. 213649  
UDIN: 26213649FMOEVF7816

Place: Hyderabad  
Date: January 23, 2026

**LAURUS LABS LIMITED**  
(CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021

Corp. Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India.

Tel: +91 040 6659 4333 ; Fax: +91 040 6659 4320 ; E-mail: [secretarial@lauruslabs.com](mailto:secretarial@lauruslabs.com); Website: [www.lauruslabs.com](http://www.lauruslabs.com)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

₹ in Crores

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
1	<b>Income</b> (a) Revenue from operations (b) Other income <b>Total income</b>	1,509.42 14.37 <b>1,523.79</b>	1,566.60 28.45 <b>1,595.05</b>	1,265.19 7.12 <b>1,272.31</b>	4,508.77 64.34 <b>4,573.11</b>	3,566.97 28.31 <b>3,595.28</b>	5,216.98 100.47 <b>5,317.45</b>
2	<b>Expenses</b> (a) Cost of materials consumed (b) Purchase of traded goods (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (Refer note 6) (e) Other expenses (f) Depreciation and amortisation expense (g) Finance costs <b>Total expenses</b>	649.72 55.12 <b>(79.17)</b> 196.29 341.60 94.31 31.48 <b>1,289.35</b>	644.40 30.70 <b>(25.58)</b> 182.31 345.11 95.59 33.68 <b>1,306.21</b>	628.75 34.79 <b>(62.60)</b> 161.70 296.27 88.66 48.02 <b>1,195.59</b>	1,867.01 124.32 <b>(105.93)</b> 558.50 1,001.97 283.47 109.05 <b>3,838.39</b>	1,766.94 83.05 <b>(168.25)</b> 459.87 875.86 270.60 133.60 <b>3,421.67</b>	2,371.38 105.36 <b>(13.55)</b> 608.64 1,200.82 358.79 182.20 <b>4,813.64</b>
3	<b>Profit before tax (1-2)</b>	<b>234.44</b>	<b>288.84</b>	<b>76.72</b>	<b>734.72</b>	<b>173.61</b>	<b>503.81</b>
4	<b>Tax expense</b> (a) Current tax (b) Deferred tax <b>Total Tax expense</b>	69.03 (9.67) <b>59.36</b>	87.93 (14.76) <b>73.17</b>	32.54 (13.09) <b>19.45</b>	216.62 (30.59) <b>186.03</b>	71.77 (26.65) <b>45.12</b>	153.84 (30.42) <b>123.42</b>
5	<b>Net Profit after tax (3-4)</b>	<b>175.08</b>	<b>215.67</b>	<b>57.27</b>	<b>548.69</b>	<b>128.49</b>	<b>380.39</b>
6	<b>Other comprehensive income</b> Items that will not be reclassified subsequently to profit or loss: (i) Remeasurement gains/(losses) on defined benefit plans (ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods <b>Total other comprehensive income /(loss), net of tax</b>	(2.30) 0.58 <b>(1.72)</b>	(0.26) 0.07 <b>(0.19)</b>	0.38 (0.10) <b>0.28</b>	(2.81) 0.71 <b>(2.10)</b>	1.14 (0.29) <b>0.85</b>	(1.02) 0.26 <b>(0.76)</b>
7	<b>Total comprehensive income (5+6)</b>	<b>173.36</b>	<b>215.48</b>	<b>57.55</b>	<b>546.59</b>	<b>129.34</b>	<b>379.63</b>
8	Paid-up equity share capital (face value ₹ 2/- each)	107.97	107.96	107.85	107.97	107.85	107.85
9	Other equity						4,456.10
10	<b>Earnings per equity share (face value ₹ 2/- each)</b> - Basic (₹) - Diluted (₹)	3.25 3.23	3.99 3.99	1.06 1.06	10.17 10.15	2.38 2.38	7.06 7.05
		<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Net annualised)</i>	<i>(Net annualised)</i>	<i>(Net annualised)</i>	<i>(Annualised)</i>

See accompanying notes to the financial results



**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E [info@lauruslabs.com](mailto:info@lauruslabs.com), W [lauruslabs.com](http://lauruslabs.com)

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

**Notes:**

- 1 The above standalone unaudited financial results of Laurus Labs Limited ("the Company") has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 23, 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2025.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 4 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the standalone financial results of the Company for the quarter and nine months ended December 31, 2025, quarter ended September 30, 2025, quarter and nine months ended December 31, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger.
- 5 During the quarter ended December 31, 2025, the Company allotted 31,683 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- 6 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Company is in the process of evaluating the full impact of these new labour codes announced. The Company continues to monitor the finalisation of Central/State Rules and Clarifications from the Government on the other aspects of New Labour Code. The Company has estimated and accounted for incremental liability for employees of ₹ 8 Crores, which is not material to the financial results.

By order of the Board  
For Laurus Labs Limited

Dr. Satyanarayana Chava  
Whole Time Director & Chief Executive Officer

Place: Hyderabad  
Date : January 23, 2026



**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**C Manish Muralidhar**  
Partner  
Membership No. 213649  
UDIN: 26213649RGCHEI5273

Place: Hyderabad  
Date: January 23, 2026